Latest News and Press Releases
Want to stay updated on the latest news?
-
Dosing in second Phase 1 clinical trial with intranasal betahistine nearing completion Approaching important interactions with regulatory agencies Progressing with strategic repositioning of...
-
Zug, Switzerland, August 09, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
-
Zug, Switzerland - July 12, 2018 - Auris Medical Holding AG (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
-
Zug, Switzerland, July 3, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and...
-
Zug, Switzerland, May 30, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and...
-
Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results
Expansion of intranasal betahistine program into mental health supportive care Initiating project AM-201 for the treatment of histaminergic receptor mediated weight gain and drowsiness in...
-
Zug, Switzerland, May 14, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
-
Design for single pivotal phase 3 trial validated by European Medicines Agency Regulatory pathway towards European market approval mapped out Strategy update scheduled together with...
-
Zug, Switzerland, May 4, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
-
Zug, Switzerland, April 9, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...